Novartis Bioventures Ltd - Net Worth and Insider Trading

Novartis Bioventures Ltd Net Worth

The estimated net worth of Novartis Bioventures Ltd is at least $169 Million dollars as of 2024-11-13. Novartis Bioventures Ltd is the 10% Owner of Ra Pharmaceuticals Inc and owns about 2,251,457 shares of Ra Pharmaceuticals Inc (RARX) stock worth over $108 Million. Novartis Bioventures Ltd is the 10% Owner of Bicycle Therapeutics PLC and owns about 1,769,641 shares of Bicycle Therapeutics PLC (BCYC) stock worth over $41 Million. Novartis Bioventures Ltd is also the of Akouos Inc and owns about 1,181,258 shares of Akouos Inc (AKUS) stock worth over $16 Million. Besides these, Novartis Bioventures Ltd also holds Spyre Therapeutics Inc (SYRE) , Aerpio Pharmaceuticals Inc (ARPO) , Aileron Therapeutics Inc (ALRN) , Galera Therapeutics Inc (GRTX) , Proteostasis Therapeutics Inc (PTI) . Details can be seen in Novartis Bioventures Ltd's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Novartis Bioventures Ltd has not made any transactions after 2020-06-30 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Novartis Bioventures Ltd

Novartis Bioventures Ltd Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Novartis Bioventures Ltd owns 17 companies in total, including Akouos Inc (AKUS) , Forma Therapeutics Holdings Inc (FMTX) , and Galera Therapeutics Inc (GRTX) among others .

Click here to see the complete history of Novartis Bioventures Ltd’s form 4 insider trades.

Insider Ownership Summary of Novartis Bioventures Ltd

Ticker	Comapny	Transaction Date	Type of Owner
AKUS	Akouos Inc	2020-06-30	10 percent owner
FMTX	Forma Therapeutics Holdings Inc	2020-06-18	10 percent owner
GRTX	Galera Therapeutics Inc	2020-06-19	10 percent owner
		2019-05-28	10 percent owner
		2019-04-26	10 percent owner
		2019-04-01	10 percent owner
		2017-05-04	10 percent owner
		2018-05-11	10 percent owner
		2017-06-19	10 percent owner
		2016-02-17	10 percent owner
		2014-09-16	10 percent owner
		2014-03-19	10 percent owner
		2014-01-29	10 percent owner
		2010-07-21	10 percent owner
		2017-03-15	10 percent owner
		2016-02-10	10 percent owner
		2016-02-10	10 percent owner

Novartis Bioventures Ltd Latest Holdings Summary

Novartis Bioventures Ltd currently owns a total of 8 stocks. Among these stocks, Novartis Bioventures Ltd owns 2,251,457 shares of Ra Pharmaceuticals Inc (RARX) as of June 19, 2017, with a value of $108 Million and a weighting of 63.75%. Novartis Bioventures Ltd owns 1,769,641 shares of Bicycle Therapeutics PLC (BCYC) as of May 28, 2019, with a value of $41 Million and a weighting of 24.43%. Novartis Bioventures Ltd also owns 1,181,258 shares of Akouos Inc (AKUS) as of June 30, 2020, with a value of $16 Million and a weighting of 9.26%. The other 5 stocks Spyre Therapeutics Inc (SYRE) , Aerpio Pharmaceuticals Inc (ARPO) , Aileron Therapeutics Inc (ALRN) , Galera Therapeutics Inc (GRTX) , Proteostasis Therapeutics Inc (PTI) have a combined weighting of 2.55% among all his current holdings.

Latest Holdings of Novartis Bioventures Ltd

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
RARX	Ra Pharmaceuticals Inc	2017-06-19	2,251,457	47.99	108,047,421
BCYC	Bicycle Therapeutics PLC	2019-05-28	1,769,641	23.40	41,409,599
AKUS	Akouos Inc	2020-06-30	1,181,258	13.29	15,698,919
SYRE	Spyre Therapeutics Inc	2018-05-11	87,013	35.75	3,110,715
ARPO	Aerpio Pharmaceuticals Inc	2019-04-26	269,988	2.20	593,974
ALRN	Aileron Therapeutics Inc	2019-04-01	103,970	3.83	398,205
GRTX	Galera Therapeutics Inc	2020-06-19	2,467,961	0.05	123,398
PTI	Proteostasis Therapeutics Inc	2016-02-17	93,690	1.11	103,996

Holding Weightings of Novartis Bioventures Ltd

Novartis Bioventures Ltd Form 4 Trading Tracker

According to the SEC Form 4 filings, Novartis Bioventures Ltd has made a total of 0 transactions in Ra Pharmaceuticals Inc (RARX) over the past 5 years. The most-recent trade in Ra Pharmaceuticals Inc is the sale of 56,420 shares on June 19, 2017, which brought Novartis Bioventures Ltd around $1 Million.

According to the SEC Form 4 filings, Novartis Bioventures Ltd has made a total of 0 transactions in Bicycle Therapeutics PLC (BCYC) over the past 5 years. The most-recent trade in Bicycle Therapeutics PLC is the acquisition of 168,630 shares on May 28, 2019, which cost Novartis Bioventures Ltd around $2 Million.

According to the SEC Form 4 filings, Novartis Bioventures Ltd has made a total of 1 transactions in Akouos Inc (AKUS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Akouos Inc is the acquisition of 125,000 shares on June 30, 2020, which cost Novartis Bioventures Ltd around $2 Million.

More details on Novartis Bioventures Ltd's insider transactions can be found in the Insider Trading History of Novartis Bioventures Ltd table.

Insider Trading History of Novartis Bioventures Ltd

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Novartis Bioventures Ltd Trading Performance

GuruFocus tracks the stock performance after each of Novartis Bioventures Ltd's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Novartis Bioventures Ltd is 9.13%. GuruFocus also compares Novartis Bioventures Ltd's trading performance to market benchmark return within the same time period. The performance of stocks bought by Novartis Bioventures Ltd within 3 months outperforms 3 times out of 7 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Novartis Bioventures Ltd's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Novartis Bioventures Ltd

Average Return

Average return per transaction

Outperforming Transactions

3 out of 7 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-1.78
Relative Return to S&P 500(%)	-5.07

Novartis Bioventures Ltd Ownership Network

Ownership Network List of Novartis Bioventures Ltd

No Data

Ownership Network Relation of Novartis Bioventures Ltd

Novartis Bioventures Ltd Owned Company Details

What does Akouos Inc do?

Who are the key executives at Akouos Inc?

Novartis Bioventures Ltd is the 10 percent owner of Akouos Inc. Other key executives at Akouos Inc include 10 percent owner Kearny Acquisition Corp , 10 percent owner Lilly Eli & Co , and Chief Operating Officer Jennifer Anne Wellman .

Akouos Inc (AKUS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Akouos Inc (AKUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Akouos Inc (AKUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Akouos Inc (AKUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Akouos Inc Insider Transactions

No Available Data

What does Forma Therapeutics Holdings Inc do?

Who are the key executives at Forma Therapeutics Holdings Inc?

Novartis Bioventures Ltd is the 10 percent owner of Forma Therapeutics Holdings Inc. Other key executives at Forma Therapeutics Holdings Inc include EVP & Research & Development Agustin Melian , SVP & Chief Scientific Officer David N Cook , and SVP & Chief Financial Officer Todd Shegog .

Forma Therapeutics Holdings Inc (FMTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Forma Therapeutics Holdings Inc (FMTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Forma Therapeutics Holdings Inc (FMTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Forma Therapeutics Holdings Inc (FMTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Forma Therapeutics Holdings Inc Insider Transactions

No Available Data

What does Galera Therapeutics Inc do?

Who are the key executives at Galera Therapeutics Inc?

Novartis Bioventures Ltd is the 10 percent owner of Galera Therapeutics Inc. Other key executives at Galera Therapeutics Inc include director & President and CEO Mel Sorensen , Chief Commercial Officer Mark Bachleda , and Chief Financial Officer Chris Degnan .

Galera Therapeutics Inc (GRTX) Insider Trades Summary

Over the past 18 months, Novartis Bioventures Ltd made no insider transaction in Galera Therapeutics Inc (GRTX). Other recent insider transactions involving Galera Therapeutics Inc (GRTX) include a net purchase of 3,712,809 shares made by , and a net sale of 67,015 shares made by Mel Sorensen .

In summary, during the past 3 months, insiders sold 67,015 shares of Galera Therapeutics Inc (GRTX) in total and bought 0 shares, with a net sale of 67,015 shares. During the past 18 months, 67,015 shares of Galera Therapeutics Inc (GRTX) were sold and 3,712,809 shares were bought by its insiders, resulting in a net purchase of 3,645,794 shares.

Galera Therapeutics Inc (GRTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Galera Therapeutics Inc Insider Transactions

No Available Data

What does Bicycle Therapeutics PLC do?

Who are the key executives at Bicycle Therapeutics PLC?

Novartis Bioventures Ltd is the 10 percent owner of Bicycle Therapeutics PLC. Other key executives at Bicycle Therapeutics PLC include Chief Operating Officer Michael Skynner , Chief Accounting Officer Travis Alvin Thompson , and Chief Operating Officer Alistair Milnes .

Bicycle Therapeutics PLC (BCYC) Insider Trades Summary

Over the past 18 months, Novartis Bioventures Ltd made no insider transaction in Bicycle Therapeutics PLC (BCYC). Other recent insider transactions involving Bicycle Therapeutics PLC (BCYC) include a net sale of 21,235 shares made by Kevin Lee , a net sale of 6,430 shares made by Michael Skynner , and a net sale of 6,430 shares made by Nigel Crockett .

In summary, during the past 3 months, insiders sold 6,528 shares of Bicycle Therapeutics PLC (BCYC) in total and bought 0 shares, with a net sale of 6,528 shares. During the past 18 months, 47,264 shares of Bicycle Therapeutics PLC (BCYC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 47,264 shares.

Bicycle Therapeutics PLC (BCYC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Bicycle Therapeutics PLC Insider Transactions

No Available Data

What does Aerpio Pharmaceuticals Inc do?

Who are the key executives at Aerpio Pharmaceuticals Inc?

Novartis Bioventures Ltd is the 10 percent owner of Aerpio Pharmaceuticals Inc. Other key executives at Aerpio Pharmaceuticals Inc include director & 10 percent owner Orbimed Advisors Llc , Vice President of Finance Regina Marek , and director & President Joseph H. Gardner .

Aerpio Pharmaceuticals Inc (ARPO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aerpio Pharmaceuticals Inc (ARPO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aerpio Pharmaceuticals Inc (ARPO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aerpio Pharmaceuticals Inc (ARPO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aerpio Pharmaceuticals Inc Insider Transactions

No Available Data

What does Aileron Therapeutics Inc do?

Who are the key executives at Aileron Therapeutics Inc?

Novartis Bioventures Ltd is the 10 percent owner of Aileron Therapeutics Inc. Other key executives at Aileron Therapeutics Inc include See Remarks James Brian Windsor , See Remarks Susan L. Drexler , and 10 percent owner Muneer A Satter .

Aileron Therapeutics Inc (ALRN) Insider Trades Summary

Over the past 18 months, Novartis Bioventures Ltd made no insider transaction in Aileron Therapeutics Inc (ALRN). Other recent insider transactions involving Aileron Therapeutics Inc (ALRN) include a net sale of 95,059 shares made by , and a net purchase of 5,301 shares made by James Brian Windsor .

In summary, during the past 3 months, insiders sold 0 shares of Aileron Therapeutics Inc (ALRN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 95,059 shares of Aileron Therapeutics Inc (ALRN) were sold and 5,301 shares were bought by its insiders, resulting in a net sale of 89,758 shares.

Aileron Therapeutics Inc (ALRN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aileron Therapeutics Inc Insider Transactions

No Available Data

What does Altimmune Inc do?

Who are the key executives at Altimmune Inc?

Novartis Bioventures Ltd is the 10 percent owner of Altimmune Inc. Other key executives at Altimmune Inc include Chief Financial Officer Richard I Eisenstadt , Chief Medical Officer Matthew Scott Harris , and Chief Business Officer Raymond M Jordt .

Altimmune Inc (ALT) Insider Trades Summary

Over the past 18 months, Novartis Bioventures Ltd made no insider transaction in Altimmune Inc (ALT). Other recent insider transactions involving Altimmune Inc (ALT) include a net sale of 15,711 shares made by David Drutz ,

In summary, during the past 3 months, insiders sold 16,011 shares of Altimmune Inc (ALT) in total and bought 0 shares, with a net sale of 16,011 shares. During the past 18 months, 16,011 shares of Altimmune Inc (ALT) were sold and 300 shares were bought by its insiders, resulting in a net sale of 15,711 shares.

Altimmune Inc (ALT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Altimmune Inc Insider Transactions

No Available Data

What does Spyre Therapeutics Inc do?

Who are the key executives at Spyre Therapeutics Inc?

Novartis Bioventures Ltd is the 10 percent owner of Spyre Therapeutics Inc. Other key executives at Spyre Therapeutics Inc include Chief Financial Officer Scott L Burrows , See Remarks Heidy King-jones , and director & 10 percent owner Fairmount Healthcare Co-invest L.p. .

Spyre Therapeutics Inc (SYRE) Insider Trades Summary

Over the past 18 months, Novartis Bioventures Ltd made no insider transaction in Spyre Therapeutics Inc (SYRE). Other recent insider transactions involving Spyre Therapeutics Inc (SYRE) include a net sale of 7,000 shares made by Jeffrey W. Albers , and a net sale of 18,531 shares made by Scott L Burrows .

In summary, during the past 3 months, insiders sold 25,531 shares of Spyre Therapeutics Inc (SYRE) in total and bought 0 shares, with a net sale of 25,531 shares. During the past 18 months, 25,531 shares of Spyre Therapeutics Inc (SYRE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 25,531 shares.

Spyre Therapeutics Inc (SYRE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Spyre Therapeutics Inc Insider Transactions

No Available Data

What does Ra Pharmaceuticals Inc do?

Who are the key executives at Ra Pharmaceuticals Inc?

Novartis Bioventures Ltd is the 10 percent owner of Ra Pharmaceuticals Inc. Other key executives at Ra Pharmaceuticals Inc include director & President and CEO Douglas A Treco , 10 percent owner New Enterprise Associates 13 Lp , and director & 10 percent owner Rajeev M. Shah .

Ra Pharmaceuticals Inc (RARX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Ra Pharmaceuticals Inc (RARX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ra Pharmaceuticals Inc (RARX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Ra Pharmaceuticals Inc (RARX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ra Pharmaceuticals Inc Insider Transactions

No Available Data

What does Proteostasis Therapeutics Inc do?

Who are the key executives at Proteostasis Therapeutics Inc?

Novartis Bioventures Ltd is the 10 percent owner of Proteostasis Therapeutics Inc. Other key executives at Proteostasis Therapeutics Inc include Interim Head of Finance Michael Alfieri , Chief Scientific Officer Benito Munoz , and See Remarks Eric D Larson .

Proteostasis Therapeutics Inc (PTI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Proteostasis Therapeutics Inc (PTI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Proteostasis Therapeutics Inc (PTI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Proteostasis Therapeutics Inc (PTI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Proteostasis Therapeutics Inc Insider Transactions

No Available Data

What does Eledon Pharmaceuticals Inc do?

Who are the key executives at Eledon Pharmaceuticals Inc?

Novartis Bioventures Ltd is the 10 percent owner of Eledon Pharmaceuticals Inc. Other key executives at Eledon Pharmaceuticals Inc include other: See Explanation of Responses Biotechnology Value Fund L P , director & See Remarks Steven Perrin , and director & Chief Executive Officer David-alexandre C Gros .

Eledon Pharmaceuticals Inc (ELDN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Eledon Pharmaceuticals Inc (ELDN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eledon Pharmaceuticals Inc (ELDN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Eledon Pharmaceuticals Inc (ELDN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eledon Pharmaceuticals Inc Insider Transactions

No Available Data

What does Akebia Therapeutics Inc do?

Who are the key executives at Akebia Therapeutics Inc?

Novartis Bioventures Ltd is the 10 percent owner of Akebia Therapeutics Inc. Other key executives at Akebia Therapeutics Inc include SVP & General Counsel & Sec. Nicole R. Hadas , SVP & Chief Business Officer Michel Dahan , and director & CEO & President John P. Butler .

Akebia Therapeutics Inc (AKBA) Insider Trades Summary

Over the past 18 months, Novartis Bioventures Ltd made no insider transaction in Akebia Therapeutics Inc (AKBA). Other recent insider transactions involving Akebia Therapeutics Inc (AKBA) include a net sale of 149,723 shares made by Michel Dahan , a net sale of 106,103 shares made by Steven Keith Burke , and a net sale of 88,587 shares made by Nicole R. Hadas .

In summary, during the past 3 months, insiders sold 0 shares of Akebia Therapeutics Inc (AKBA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 492,283 shares of Akebia Therapeutics Inc (AKBA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 492,283 shares.

Akebia Therapeutics Inc (AKBA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Akebia Therapeutics Inc Insider Transactions

No Available Data

What does Eiger BioPharmaceuticals Inc do?

Who are the key executives at Eiger BioPharmaceuticals Inc?

Novartis Bioventures Ltd is the 10 percent owner of Eiger BioPharmaceuticals Inc. Other key executives at Eiger BioPharmaceuticals Inc include 10 percent owner Richard A Kayne , 10 percent owner Leen Kawas , and Chief Business Officer Ingrid Choong .

Eiger BioPharmaceuticals Inc (EIGRQ) Insider Trades Summary

Over the past 18 months, Novartis Bioventures Ltd made no insider transaction in Eiger BioPharmaceuticals Inc (EIGRQ). Other recent insider transactions involving Eiger BioPharmaceuticals Inc (EIGRQ) include a net purchase of 278,239 shares made by Richard A Kayne , and a net purchase of 24,332 shares made by Leen Kawas .

In summary, during the past 3 months, insiders sold 0 shares of Eiger BioPharmaceuticals Inc (EIGRQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eiger BioPharmaceuticals Inc (EIGRQ) were sold and 10,086 shares were bought by its insiders, resulting in a net purchase of 10,086 shares.

Eiger BioPharmaceuticals Inc (EIGRQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eiger BioPharmaceuticals Inc Insider Transactions

No Available Data

What does Adhera Therapeutics Inc do?

Who are the key executives at Adhera Therapeutics Inc?

Novartis Bioventures Ltd is the 10 percent owner of Adhera Therapeutics Inc. Other key executives at Adhera Therapeutics Inc include director & Chief Executive Officer Andrew Albert Kucharchuk , SVP Finance & Accounting Rhonda L. Stanley , and Chief Financial Officer Robert Eric Teague .

Adhera Therapeutics Inc (ATRX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Adhera Therapeutics Inc (ATRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Adhera Therapeutics Inc (ATRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Adhera Therapeutics Inc (ATRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Adhera Therapeutics Inc Insider Transactions

No Available Data

What does Aadi Bioscience Inc do?

Who are the key executives at Aadi Bioscience Inc?

Novartis Bioventures Ltd is the 10 percent owner of Aadi Bioscience Inc. Other key executives at Aadi Bioscience Inc include director & Chief Executive Officer David James Lennon , director & See Remarks Neil Desai , and Chief Financial Officer Scott M. Giacobello .

Aadi Bioscience Inc (AADI) Insider Trades Summary

Over the past 18 months, Novartis Bioventures Ltd made no insider transaction in Aadi Bioscience Inc (AADI). Other recent insider transactions involving Aadi Bioscience Inc (AADI) include a net sale of 660,000 shares made by Neil Desai , and a net sale of 9,689 shares made by David James Lennon .

In summary, during the past 3 months, insiders sold 49,689 shares of Aadi Bioscience Inc (AADI) in total and bought 0 shares, with a net sale of 49,689 shares. During the past 18 months, 669,689 shares of Aadi Bioscience Inc (AADI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 669,689 shares.

Aadi Bioscience Inc (AADI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aadi Bioscience Inc Insider Transactions

No Available Data

What does Yumanity Therapeutics Inc do?

Who are the key executives at Yumanity Therapeutics Inc?

Novartis Bioventures Ltd is the 10 percent owner of Yumanity Therapeutics Inc. Other key executives at Yumanity Therapeutics Inc include director & Chief Executive Officer Shawn Iadonato , Chief Scientific Officer Thierry Guillaudeux , and Chief Financial Officer Keith Baker .

Yumanity Therapeutics Inc (YMTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Yumanity Therapeutics Inc (YMTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Yumanity Therapeutics Inc (YMTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Yumanity Therapeutics Inc (YMTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Yumanity Therapeutics Inc Insider Transactions

No Available Data

What does Kineta Inc do?

Who are the key executives at Kineta Inc?

Novartis Bioventures Ltd is the 10 percent owner of Kineta Inc. Other key executives at Kineta Inc include director & Chief Executive Officer Shawn Iadonato , President Craig W. Philips , and General Counsel Pauline Kenny .

Kineta Inc (KANT) Insider Trades Summary

Over the past 18 months, Novartis Bioventures Ltd made no insider transaction in Kineta Inc (KANT). Other recent insider transactions involving Kineta Inc (KANT) include a net purchase of 7,250 shares made by Raymond J. Bartoszek , a net purchase of 15,000 shares made by Shawn Iadonato , and a net purchase of 10,000 shares made by Keith Baker .

In summary, during the past 3 months, insiders sold 0 shares of Kineta Inc (KANT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kineta Inc (KANT) were sold and 50,250 shares were bought by its insiders, resulting in a net purchase of 50,250 shares.

Kineta Inc (KANT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kineta Inc Insider Transactions

No Available Data

Novartis Bioventures Ltd Mailing Address

Above is the net worth, insider trading, and ownership report for Novartis Bioventures Ltd. You might contact Novartis Bioventures Ltd via mailing address: C/o Novartis International Ag, Wsj-200.220, Ch-4002 Basel V8 0000000000.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.